Selecting and Rationalizing Development Projects
First written in FY2016. 5 of 8 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025Multiple development programs explicitly discontinuedAnnual report
「<SI-613> Development in the United States, China and South Korea was discontinued in light of progress in investigating the causes of shock and anaphylaxis associated with Joycl in Japan. <SI-613-ETP> Development of this project was discontinued in light of the failure to meet the primary efficacy endpoint in the domestic late Phase II clinical trial for enthesopathy of the tendon and ligament attachment sites, as well as progress in investigating the causes of shock and anaphylaxis associated with Joycl.」
With respect to the selection and streamlining of development projects, the company explicitly disclosed the discontinuation of SI-613 development in the United States, China and South Korea, and the discontinuation of SI-613-ETP development. - FY2022SI-613-ETP development suspendedAnnual report
「Development was suspended in February 2022 because the primary efficacy endpoint was not met in the domestic late Phase II clinical trial for enthesopathy of the tendon and ligament attachment sites, and because priority was given to investigating the causes of shock and anaphylaxis associated with Joycl.」
SI-613-ETP did not meet the primary efficacy endpoint in its late Phase II trial, resulting in the suspension of development as the company prioritized investigating the causes of Joycl's safety issues. - FY2022-Q2RestatedAnnual report
「We will promote efficient activities focused on selected target compounds and priority diseases, while expanding the number of projects by strengthening our proprietary drug-discovery technologies and leveraging open innovation.」
The company continues to pursue its policy of selecting and streamlining R&D projects and expanding projects through proprietary technologies and open innovation. - FY2022-Q1RestatedAnnual report
「We will promote efficient activities focused on selected target compounds and priority diseases, while expanding the number of projects by strengthening our proprietary drug-discovery technologies and leveraging open innovation.」
The company continues to pursue its policy of selecting and streamlining R&D projects and expanding projects through proprietary technologies and open innovation. - FY2021-Q3RestatedAnnual report
「To achieve the early and continuous launch of new drugs that will be key to future business growth, we will pursue efficient activities by narrowing the target substances and priority diseases, while expanding the number of projects by strengthening our proprietary drug-discovery technologies and leveraging open innovation.」
The company continues to pursue its R&D policy of narrowing target substances and priority diseases, strengthening proprietary drug-discovery technologies and expanding projects through open innovation. - FY2020-Q3RestatedAnnual report
「To achieve the early and continuous launch of new drugs that will be key to future business growth, we will pursue efficient activities by narrowing the target substances and priority diseases, while expanding the number of projects by strengthening our proprietary drug-discovery technologies and leveraging open innovation.」
The company continues to pursue R&D focused on selected target compounds and priority diseases, strengthen its proprietary technologies, and expand projects through open innovation. - FY2019RestatedAnnual report
「To achieve the early and continuous launch of new drugs that will be key to future business growth, we are promoting efficient activities focused on selected target compounds and priority diseases, while working to expand our domestic and international glycoscience research network.」
The company continues to pursue efficient R&D focused on selected target compounds and priority diseases, along with its policy of expanding its glycoscience research network. - FY2016First statedAnnual report
「As the expected efficacy could not be clearly demonstrated in the results of the Phase III clinical trial in Japan, development of this project was discontinued in February 2016.」
The company disclosed the discontinuation of SI-657 development and the termination of the licensing agreement for SI-615, indicating that it is selectively pursuing its R&D projects.